Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Interesting links
Here are some interesting links for you! Enjoy your stay :)Pages
Categories
Archive
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- August 2019
- June 2019
Bioshares Summit
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix is joining the biotech investment community at the 17th Bioshares Biotech Summit in Hobart this week.
This year’s theme is ‘partnering and financing’, and Botanix Executive Director, Matt Callahan, will be sharing insights into the Company’s progress navigating towards FDA approval for Sofpironium Bromide.
Click here to review the presentation.
The West Australian | Botanix Pharmaceuticals secures $12.5m via an institutional placement
/in Featured, Latest News, News /by Haley ChartresBotanix has been featured in an article by Cheyanne Enciso in The West Australian newspaper, reporting on its A$12.5 million raise via an institutional placement.
Read the article here.
A$12.5 million institutional placement
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix has announced it has secured firm commitments for A$12.5 million via an institutional placement.
Proceeds from this raise will be used to extinguish future milestone and royalty payments linked to Botanix’s lead product, Sofpironium Bromide (SB) – in a move that could save up to $160 million and prime the Company for potential M&A or partnership activity.
Click here to read ASX release.
Video | Investor Webinar
/in Featured, Latest News, Presentations, Videos /by Haley ChartresBotanix (ASX: BOT) hosted a webinar recently to update investors on the Company’s progress during the FDA review period for its lead product, Sofpironium Bromide.
The webinar was hosted by Executive Director, Matt Callahan and Chief Operating Officer, Howie McKibbon.
Take a look.
New territory licensed for Sofpironium Bromide with partner Kaken
/in ASX Releases, Latest News /by Haley ChartresBotanix has today announced that our partner Kaken Pharmaceutical Co Ltd, has secured a new sublicense and distribution agreement for Sofpironium Bromide in Korea.
The deal with Dong Wha Pharmaceuticals, Korea’s oldest pharmaceutical company, will see the expansion of Sofpironium Bromide into the Korean market. Sofpironium Bromide has been successfully marketed as ECCLOCK® by sublicensee Kaken in Japan since November 2020.
Under the terms of this agreement, Botanix will be entitled to a share of the upfront, milestone and royalty payments based on net sales of the products.
Botanix Executive Chairman, Vince Ippolito, said:
“We are very pleased with the progress being made by our partner Kaken in expanding the territories for Sofpironium Bromide commercialisation globally.
“Given the global incidence of primary axillary hyperhidrosis and the relative lack of effective solutions for patients, the opportunities for Sofpironium Bromide continue to expand beyond Botanix’s primary focus of the USA with our existing partner Kaken and new partners to come.”
Click here to view ASX release.
Investor Webinar Invitation
/in Featured, Latest News /by Haley ChartresBotanix (ASX: BOT) is preparing to host an upcoming investor webinar on Wednesday 07/06/23, 10:30am AEST | 8:30am AWST.
On this call, you will hear from Executive Director, Matt Callahan and Chief Operating Officer, Howie McKibbon. Together, they will be sharing an update on our progress during the current FDA-review stage for our lead product Sofpironium Bromide.
Click here to pre-register now to secure your place.